About Somai Pharmaceuticals Inc.

Somaí, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specialising in cannabinoid-based medicines, is driving the global pharmaceutical cannabis market with a broad portfolio of EU-GMP-certified extracts.

Somaí is building a global brand focused on innovative cannabis-based therapeutics, with a vision of people living healthier lives supported by natural cannabis medicines.

The core strength of Somaí lies in its EU-GMP certification, which represents the gold standard for pharmaceutical manufacturing worldwide. This is particularly important in markets like the U.K., where there is a clear distinction between fully EU-GMP pharmaceutical products and less stringently regulated “Specials” or compounded extracts.

Somaí owns and operates its facilities under this highest standard:

• Somaí Pharmaceuticals – a state-of-the-art manufacturing facility in Lisbon, Portugal
• NovaSoma – an indoor cultivation facility, also in Lisbon, Portugal

Complete vertical integration—from indoor cultivation through to finished-dose manufacturing—under strict EU-GMP rules ensures batch-to-batch consistency, long-term stability data, and chemical reproducibility for patients. This level of quality and regulatory adherence allows Somaí's products to be supplied globally as true finished-dosage pharmaceutical extracts.

This commitment to the EU-GMP pharmaceutical standard enables Somaí to compete directly with established pharmaceutical manufacturers and to build one of the most advanced certified cannabinoid-containing extract portfolios worldwide.